Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Rezolute (NASDAQ: RZLT) announced an inducement equity grant for two new employees, approved under Nasdaq Listing Rule 5635(c)(4).

The company granted options to purchase a total of 245,000 shares of common stock, with a 10-year term and an exercise price of $9.32 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service.

News Market Reaction

-7.48%

30 alerts

-7.48% News Effect

+8.1% Peak Tracked

-4.6% Trough Tracked

-$76M Valuation Impact

$940M Market Cap

1.4x Rel. Volume

On the day this news was published, RZLT declined 7.48%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.1% during that session. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $76M from the company's valuation, bringing the market cap to $940M at that time.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Rezolute.

The Company granted options to purchase 245,000 shares, in the aggregate, of Rezolute common stock to the new employees. The options have a 10-year term and an exercise price per share equal to $9.32, which was the closing price of the Company’s common stock on October 31, 2025. The options vest over four years, subject to the employees’ continued service through the applicable vesting dates.

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
  
Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

What did Rezolute (RZLT) grant on October 31, 2025?

Rezolute granted options to purchase a total of 245,000 shares to two new employees as inducement awards.

What is the exercise price and term for the RZLT inducement options?

The options have an exercise price of $9.32 per share and a 10-year term.

How do the RZLT options vest and what is the vesting period?

The options vest over four years, subject to the employees’ continued service through applicable vesting dates.

Under which Nasdaq rule were Rezolute's (RZLT) inducement awards approved?

The awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.

How many employees received the Rezolute (RZLT) inducement awards?

Two new employees received the inducement option awards in the aggregate.

Does the RZLT press release state any change to guidance or financial results?

No; the release only describes the equity inducement awards and related terms, not earnings or guidance.